摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-溴-3-异丙基-1H-吡唑 | 60061-60-1

中文名称
4-溴-3-异丙基-1H-吡唑
中文别名
——
英文名称
4-bromo-3-isopropyl-1H-pyrazole
英文别名
4-bromo-5-propan-2-yl-1H-pyrazole
4-溴-3-异丙基-1H-吡唑化学式
CAS
60061-60-1
化学式
C6H9BrN2
mdl
MFCD14657923
分子量
189.055
InChiKey
LYGXWTVFFARCIJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    267.4±20.0 °C(Predicted)
  • 密度:
    1.485±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    28.7
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:8361944ebd336f36ca281b811293c90d
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-Bromo-3-isopropyl-1H-pyrazole
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-3-isopropyl-1H-pyrazole
CAS number: 60061-60-1

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H9BrN2
Molecular weight: 189.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Trofimenko, Swiatoslaw; Calabrese, Joseph C.; Domaille, Peter J., Inorganic Chemistry, 1989, vol. 28, # 6, p. 1091 - 1101
    摘要:
    DOI:
  • 作为产物:
    描述:
    3-甲基-2-丁酮sodium methylate 作用下, 以 甲苯 为溶剂, 反应 1.58h, 生成 4-溴-3-异丙基-1H-吡唑
    参考文献:
    名称:
    Use of pyrazolyl ligands for the formation of a bimetallic cobalt–ruthenium complex
    摘要:
    A straightforward route to Ru(pyz)(2)(Hpyz)(4) (Hpyz = pyrazole) has been developed. This has been found to react readily with a modified Co(pyrazolylborate)Cl complex in the presence of triethylamine as an HCl acceptor to yield a bimetallic cobalt-ruthenium complex, in which the two metals are each six-coordinate, and bridged by three pyrazolyl anions. Both species have been characterized structurally, as has a modified Co(pyrazolylborate)(2) complex. (C) 2011 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.poly.2011.04.023
点击查看最新优质反应信息

文献信息

  • 杂芳化合物及其在药物中的应用
    申请人:广东东阳光药业有限公司
    公开号:CN106749268B
    公开(公告)日:2020-10-09
    本发明公开了杂芳化合物及其在药物中的应用,具体地,本发明提供一类杂芳化合物或其立体异构体,几何异构体,互变异构体,消旋体,氮氧化物,合物,溶剂化物,代谢产物,药学上可接受的盐或前药,以及包含所述化合物的药物组合物;本发明还公开了所述化合物或其药物组合物在制备药物中的用途,及其在治疗自体免疫疾病或增殖性疾病方面的应用。
  • [EN] AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF<br/>[FR] COMPOSÉS AMIDES, COMPOSITIONS ET APPLICATIONS DE CEUX-CI
    申请人:ADVINUS THERAPEUTICS LTD
    公开号:WO2013042139A1
    公开(公告)日:2013-03-28
    The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them. These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Fatty Acid Amide Hydrolase (FAAH), such as pain including acute and post operative pain, chronic pain, cancer pain, cancer chemotherapy induced pain, neuropathic pain, nociceptive pain, inflammatory pain, back pain, pain due to disease of various origin such as: diabetic neuropathy, neurotropic viral disease including human immunodeficient virus (HIV), herpes zoster such as post herpetic neuralgia; polyneuropathy, neurotoxicity, mechanical nerve injury, carpal tunnel syndrome, immunologic mechanisms like multiple sclerosis; sleep disorders, anxiety and depression disorders, inflammatory disorders, weight and eating disorders, Parkinson's disease, addiction, spasticity, hypertension or other disorders. The disclosure also relates to the process of preparation of the amide compounds. Formula (1). The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
    本公开涉及替代酰胺化合物,这些化合物是脂肪酸酰胺解酶(FAAH)的抑制剂,包括它们的立体异构体、互变异构体、前药、多型体、溶剂合物、药用盐以及含有它们的药物组合物。这些化合物在治疗、预防、预防、管理或辅助治疗与脂肪酸酰胺解酶(FAAH)抑制相关的所有医疗状况中非常有用,例如疼痛,包括急性和术后疼痛,慢性疼痛,癌症疼痛,癌症化疗引起的疼痛,神经痛,伤害性疼痛,炎症性疼痛,背部疼痛,疾病引起的疼痛,如糖尿病性神经病变,神经病毒性疾病,包括人类免疫缺陷病毒(HIV),带状疱疹,如带状疱疹后神经痛;多发性神经病,神经毒性,机械神经损伤,腕管综合症,类似多发性硬化的免疫机制;睡眠障碍,焦虑和抑郁症,炎症性疾病,体重和进食障碍,帕森病,成瘾,痉挛,高血压或其他疾病。该公开还涉及酰胺化合物的制备过程。公式(1)。本公开还涉及制备这类化合物的方法,以及含有它们的药物组合物。
  • AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF
    申请人:ADVINUS THERAPEUTICS LIMITED
    公开号:US20150065464A1
    公开(公告)日:2015-03-05
    The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them. These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Fatty Acid Amide Hydrolase (FAAH), such as pain including acute and post operative pain, chronic pain, cancer pain, cancer chemotherapy induced pain, neuropathic pain, nociceptive pain, inflammatory pain, back pain, pain due to disease of various origin such as: diabetic neuropathy, neurotropic viral disease including human immunodeficient virus (HIV), herpes zoster such as post herpetic neuralgia; polyneuropathy, neurotoxicity, mechanical nerve injury, carpal tunnel syndrome, immunologic mechanisms like multiple sclerosis; sleep disorders, anxiety and depression disorders, inflammatory disorders, weight and eating disorders, Parkinson's disease, addiction, spasticity, hypertension or other disorders. The disclosure also relates to the process of preparation of the amide compounds. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
    本公开涉及替代酰胺化合物,它们是脂肪酸酰胺解酶(FAAH)的抑制剂,包括它们的立体异构体、互变异构体、前药、多型体、溶剂合物、药用可接受盐以及含有它们的药物组合物。这些化合物在治疗、预防、预防、管理或辅助治疗与脂肪酸酰胺解酶(FAAH)抑制相关的所有医疗状况中非常有用,如疼痛,包括急性和术后疼痛,慢性疼痛,癌症疼痛,癌症化疗引起的疼痛,神经痛,伤害性疼痛,炎症性疼痛,背部疼痛,疾病引起的疼痛,如糖尿病性神经病变,神经病毒性疾病,包括人类免疫缺陷病毒(HIV),带状疱疹,如带状疱疹后神经痛;多发性神经病,神经毒性,机械神经损伤,腕管综合症,免疫机制如多发性硬化症;睡眠障碍,焦虑和抑郁症,炎症性疾病,体重和进食障碍,帕森病,成瘾,痉挛,高血压或其他疾病。本公开还涉及酰胺化合物的制备过程。本公开还涉及制备这类化合物的方法,以及含有它们的药物组合物。
  • ISOQUINOLINES AS INHIBITORS OF HPK1
    申请人:Genentech, Inc.
    公开号:US20180282282A1
    公开(公告)日:2018-10-04
    Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibitng HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
    描述了异喹啉化合物及其作为HPK1(造血激酶1)抑制剂的用途。这些化合物在治疗依赖于HPK1的疾病和增强免疫应答方面非常有用。还描述了抑制HPK1的方法、治疗依赖于HPK1的疾病的方法、增强免疫应答的方法,以及制备异喹啉化合物的方法。
  • HETEROCYCLIC CETP INHIBITORS
    申请人:Salvati E. Mark
    公开号:US20070161685A1
    公开(公告)日:2007-07-12
    Compounds of formula Ia and Ib wherein A, B, C and R 1 are described herein.
    式Ia和Ib的化合物 其中A、B、C和R1 如本文所述。
查看更多

同类化合物

试剂2,5-Dibromo-3,4-dihexylthiophene 苯-1,2,4-三羧酸-丙烷-1,2,3-三醇(1:1) 碘吡咯 癸氯-二茂铁 甲酮,(4,5-二溴-1H-吡咯-2-基)苯基- 甲基3-氟-1H-1,2,4-三唑-5-羧酸酯 溴代二茂铁 溴-(3-溴-2-噻嗯基)镁 派瑞林D 派瑞林 F 二聚体 氯代二茂铁 曲洛酯 异噻唑,3-氯-5-甲基- 地茂酮 四碘硒吩 四碘噻吩 四碘呋喃 四溴噻吩 四溴吡咯 四溴-N-甲基吡咯 四氯噻吩 四氟噻吩 噻菌腈 噻美尼定. 噻吩,3-溴-4-(1-辛炔基)- 噻吩,3-溴-2-[2-(甲硫基)乙烯基]-,(Z)- 噻吩,3-溴-2-[2-(甲硫基)乙烯基]-,(E)- 噻吩,3-溴-2-[2-(甲硫基)乙烯基]-,(E)- 噻吩,2,5-二氯-3,4-二(氯甲基)- 喷贝特 咪唑烷,2-(4-溴-5-甲基-2-呋喃基)-1,3-二甲基- 叔丁基2-溴-4,6-二氢-5H-吡咯并[3,4-D]噻唑-5-羧酸酯 叔-丁基3-溴-6,7-二氢-1H-吡唑并[4,3-C]吡啶-5(4H)-甲酸基酯 叔-丁基2-溴-5,6-二氢咪唑并[1,2-A]吡嗪-7(8H)-甲酸基酯 叔-丁基(4-溴-5-氰基-1-甲基-1H-吡唑-3-基)氨基甲酯 双环[4.2.0]辛-1,3,5-三烯-7-甲腈,2-氟- 八氟联苯烯 八氟二苯并硒吩 全氟苯并环丁烯二酮 二苯基氯化碘盐 二联苯碘硫酸盐 二氯对二甲苯二聚体 二氯[2-甲基-3(2H)-异噻唑酮-O]的钙合物 二氯-1,2-二硫环戊烯酮 二-(3-溴-1,2,4-噻二唑-5-基)-二硫醚 二(2-噻吩基)碘鎓 乙酸,[[[1-(3-溴-5-异[口噁]唑基)亚乙基]氨基]氧代]-,甲基酯,(E)- [四丁基铵][Δ-三(四氯-1,2-苯二醇酸根)磷酸盐(V)] [3-(4-氯-3,5-二甲基-1H-吡唑-1-基)丙基]胺 [3-(4-氯-1H-吡唑-1-基)-2-甲基丙基]胺